JP2015523072A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523072A5 JP2015523072A5 JP2015520567A JP2015520567A JP2015523072A5 JP 2015523072 A5 JP2015523072 A5 JP 2015523072A5 JP 2015520567 A JP2015520567 A JP 2015520567A JP 2015520567 A JP2015520567 A JP 2015520567A JP 2015523072 A5 JP2015523072 A5 JP 2015523072A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- purified recombinant
- seq
- conversion
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000006243 chemical reaction Methods 0.000 claims 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 12
- 235000018102 proteins Nutrition 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 230000000694 effects Effects 0.000 claims 11
- 238000003556 assay Methods 0.000 claims 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 8
- 238000000338 in vitro Methods 0.000 claims 8
- 239000004471 Glycine Substances 0.000 claims 6
- 150000001413 amino acids Chemical group 0.000 claims 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 3
- 229960002897 heparin Drugs 0.000 claims 3
- 229920000669 heparin Polymers 0.000 claims 3
- -1 heparin disaccharide Chemical class 0.000 claims 3
- 239000000758 substrate Substances 0.000 claims 3
- UGJBHEZMOKVTIM-UHFFFAOYSA-N N-formylglycine Chemical compound OC(=O)CNC=O UGJBHEZMOKVTIM-UHFFFAOYSA-N 0.000 claims 2
- 229920001542 oligosaccharide Polymers 0.000 claims 2
- 150000002482 oligosaccharides Chemical class 0.000 claims 2
- 238000007670 refining Methods 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 125000005629 sialic acid group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261666733P | 2012-06-29 | 2012-06-29 | |
| US61/666,733 | 2012-06-29 | ||
| PCT/US2013/048561 WO2014005014A2 (en) | 2012-06-29 | 2013-06-28 | Purification of iduronate-2-sulfatase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016060910A Division JP6505629B2 (ja) | 2012-06-29 | 2016-03-24 | 組換えイズロン酸２スルファターゼの精製 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015523072A JP2015523072A (ja) | 2015-08-13 |
| JP2015523072A5 true JP2015523072A5 (enExample) | 2016-01-07 |
| JP6171007B2 JP6171007B2 (ja) | 2017-07-26 |
Family
ID=49778401
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015520567A Active JP6171007B2 (ja) | 2012-06-29 | 2013-06-28 | 組換えイズロン酸２スルファターゼの精製 |
| JP2016060910A Active JP6505629B2 (ja) | 2012-06-29 | 2016-03-24 | 組換えイズロン酸２スルファターゼの精製 |
| JP2018067404A Withdrawn JP2018121645A (ja) | 2012-06-29 | 2018-03-30 | 組換えイズロン酸２スルファターゼの精製 |
| JP2020037811A Active JP7594365B2 (ja) | 2012-06-29 | 2020-03-05 | 組換えイズロン酸２スルファターゼの精製 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016060910A Active JP6505629B2 (ja) | 2012-06-29 | 2016-03-24 | 組換えイズロン酸２スルファターゼの精製 |
| JP2018067404A Withdrawn JP2018121645A (ja) | 2012-06-29 | 2018-03-30 | 組換えイズロン酸２スルファターゼの精製 |
| JP2020037811A Active JP7594365B2 (ja) | 2012-06-29 | 2020-03-05 | 組換えイズロン酸２スルファターゼの精製 |
Country Status (39)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2997976A1 (en) | 2007-07-27 | 2016-03-23 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
| WO2011044542A1 (en) | 2009-10-09 | 2011-04-14 | Armagen Technologies, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| US20160145589A1 (en) | 2011-06-24 | 2016-05-26 | Green Cross Corporation | Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof |
| KR101158673B1 (ko) | 2011-06-24 | 2012-07-03 | 주식회사 지씨바이오 | 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법 |
| US9150841B2 (en) | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
| KR101380740B1 (ko) * | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| MX389073B (es) | 2016-08-25 | 2025-03-20 | Japan Chem Res | Método para producir una proteína de fusión de anticuerpo. |
| CN106282231B (zh) * | 2016-09-06 | 2020-01-03 | 陕西慧康生物科技有限责任公司 | 粘多糖贮积症ii型动物模型的构建方法及应用 |
| CN106428420B (zh) * | 2016-10-17 | 2018-08-21 | 上海江南长兴造船有限责任公司 | 一种用于超大型集装箱船止裂钢舱口围的安装的方法 |
| MX2020002918A (es) | 2017-10-02 | 2020-07-22 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas. |
| US12268733B2 (en) | 2018-08-10 | 2025-04-08 | Alexion Pharmaceuticals, Inc. | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase |
| WO2020132452A1 (en) * | 2018-12-20 | 2020-06-25 | Shire Human Genetic Therapies, Inc. | Purification of iduronate-2-sulfatase immunoglobulin fusion protein |
| WO2020160133A1 (en) * | 2019-01-30 | 2020-08-06 | Amgen Inc. | Aflibercept attributes and methods of characterizing and modifying thereof |
| IL293616A (en) | 2019-12-09 | 2022-08-01 | Alexion Pharma Inc | Alkaline phosphatase polypeptides and methods of using them |
| KR20230088811A (ko) * | 2020-10-23 | 2023-06-20 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼리성 포스파타제의 제조 동안 총 시알산 함량(tsac)을 제어하는 방법 |
| MX2023009463A (es) | 2021-02-12 | 2023-09-21 | Alexion Pharma Inc | Polipeptidos de fosfatasa alcalina y metodos para su uso. |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK6488D0 (da) | 1988-01-07 | 1988-01-07 | Novo Industri As | Enzymer |
| US5310646A (en) | 1988-05-13 | 1994-05-10 | Regents Of The University Of Minnesota | Method for the detection of mucopolysaccharide storage diseases |
| US5932211A (en) * | 1991-11-12 | 1999-08-03 | Women's And Children's Hospital | Glycosylation variants of iduronate 2-sulfatase |
| EP0750511B1 (en) | 1994-03-16 | 2003-06-11 | The Regents Of The University Of California | Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor |
| US5863782A (en) | 1995-04-19 | 1999-01-26 | Women's And Children's Hospital | Synthetic mammalian sulphamidase and genetic sequences encoding same |
| DE19527054A1 (de) | 1995-07-26 | 1997-01-30 | Behringwerke Ag | Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen |
| AU4330597A (en) | 1996-08-30 | 1998-03-19 | Life Technologies, Inc. | Serum-free mammalian cell culture medium, and uses thereof |
| US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
| US7083793B2 (en) | 1999-02-26 | 2006-08-01 | Millennium Pharmaceuticals, Inc. | Tango 243 polypeptides and uses thereof |
| WO2000050443A2 (en) | 1999-02-26 | 2000-08-31 | Millennium Pharmaceutcals, Inc. | Secreted proteins and uses thereof |
| DE60032349T2 (de) | 1999-04-26 | 2007-07-12 | Genentech, Inc., South San Francisco | Zellenzuchtverfahren für glycoproteine |
| JP2002017376A (ja) | 1999-07-08 | 2002-01-22 | Herikkusu Kenkyusho:Kk | 分泌蛋白質、または膜蛋白質 |
| AU7099200A (en) | 1999-09-03 | 2001-04-10 | Human Genome Sciences, Inc. | 52 human secreted proteins |
| US6780627B1 (en) | 2000-01-31 | 2004-08-24 | Millennium Pharmaceuticals, Inc. | 22438, 23553, 25278, and 26212 novel human sulfatases |
| EP1255819A2 (en) | 2000-02-17 | 2002-11-13 | Incyte Genomics, Inc. | Human kinases |
| CA2400638A1 (en) | 2000-03-17 | 2001-09-27 | Human Genome Sciences, Inc. | 7 human ovarian and ovarian cancer associated proteins |
| ES2529300T3 (es) | 2000-04-12 | 2015-02-18 | Novozymes Biopharma Dk A/S | Proteínas de fusión de albúmina |
| US20030148920A1 (en) | 2000-12-27 | 2003-08-07 | Steven Rosen | Sulfatases and methods of use thereof |
| WO2002098455A2 (en) | 2001-06-07 | 2002-12-12 | Hemebiotech A/S | Production of recombinant human arylsulfatase a |
| EP1501369B1 (en) | 2002-04-26 | 2015-06-24 | Genentech, Inc. | Non-affinity purification of proteins |
| US6890736B1 (en) | 2002-09-20 | 2005-05-10 | Immunex Corporation | Methods for producing proteins in cultured cells |
| KR20050088136A (ko) | 2002-12-23 | 2005-09-01 | 브리스톨-마이어스 스큅 컴퍼니 | 단백질 생산을 위한 포유류 세포 배양 방법 |
| JP4606712B2 (ja) * | 2003-01-08 | 2011-01-05 | マサチューセッツ インスティテュート オブ テクノロジー | ２−ｏスルファターゼ組成物および関連の方法 |
| CN1759176B (zh) | 2003-02-11 | 2012-10-03 | 夏尔人类遗传性治疗公司 | 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗 |
| US20050019914A1 (en) | 2003-07-24 | 2005-01-27 | Aventis Pharma Deutschland Gmbh | Perfusion process for producing erythropoietin |
| JP4586027B2 (ja) | 2004-01-30 | 2010-11-24 | シャイア ファーマシューティカルズ アイルランド リミテッド | 組換えアリールスルファターゼａの製造及び精製 |
| WO2005113765A2 (en) | 2004-05-06 | 2005-12-01 | Biomarin Pharmaceutical Inc. | Methods of activation of sulfatases and methods and compositions of using the same |
| JP5199073B2 (ja) | 2005-06-03 | 2013-05-15 | アレス トレーディング ソシエテ アノニム | 組換えｉｌ−１８結合タンパク質の生産 |
| CA2645739A1 (en) | 2006-03-20 | 2007-09-27 | Medarex, Inc. | Protein purification |
| JP4458377B2 (ja) | 2007-06-29 | 2010-04-28 | キヤノン株式会社 | プロセスカートリッジ及び電子写真画像形成装置 |
| US20130195888A1 (en) | 2007-11-30 | 2013-08-01 | Abbvie | Ultrafiltration and diafiltration formulation methods for protein processing |
| EP3219795B1 (en) * | 2008-01-18 | 2024-03-13 | BioMarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
| WO2011044542A1 (en) | 2009-10-09 | 2011-04-14 | Armagen Technologies, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| JPWO2011108451A1 (ja) * | 2010-03-01 | 2013-06-27 | 日本ケミカルリサーチ株式会社 | 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法 |
| WO2011163652A2 (en) * | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b |
| ME03649B (me) | 2010-06-25 | 2020-07-20 | Shire Human Genetic Therapies | Postupci i kompozicije za isporuku iduronat-2-sulfataze u cns |
| AR082319A1 (es) | 2010-07-22 | 2012-11-28 | Biomarin Pharm Inc | Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos |
| EP2623118A4 (en) | 2010-09-28 | 2014-05-07 | Kyoritsu Seiyaku Corp | MUCOSAL ADJUVANT COMPOSITION |
| WO2012101671A1 (en) * | 2011-01-25 | 2012-08-02 | Jcr Pharmaceuticals Co., Ltd. | Method for production of human recombinant iduronate 2-sulfatase |
| KR20130114704A (ko) | 2011-01-31 | 2013-10-17 | 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. | 동적으로 튜닝 가능한 산란각을 갖는 산광기 |
| KR101158673B1 (ko) | 2011-06-24 | 2012-07-03 | 주식회사 지씨바이오 | 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법 |
| US20140004097A1 (en) | 2012-06-29 | 2014-01-02 | Shire Human Genetic Therapies, Inc. | Method of producing recombinant iduronate-2-sulfatase |
| KR101380740B1 (ko) * | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| US9150841B2 (en) | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
| KR20190062745A (ko) | 2017-11-29 | 2019-06-07 | 주식회사 위니플 | 쇼핑몰 모바일앱 빌더 |
-
2012
- 2012-09-07 KR KR1020120099511A patent/KR101380740B1/ko active Active
-
2013
- 2013-03-14 US US13/829,706 patent/US9051556B2/en active Active
- 2013-06-28 MY MYPI2016000157A patent/MY180287A/en unknown
- 2013-06-28 MX MX2019008914A patent/MX393364B/es unknown
- 2013-06-28 PE PE2014002539A patent/PE20150720A1/es active IP Right Grant
- 2013-06-28 CN CN201710840704.3A patent/CN107596358A/zh active Pending
- 2013-06-28 EA EA202090044A patent/EA202090044A1/ru unknown
- 2013-06-28 WO PCT/US2013/048561 patent/WO2014005014A2/en not_active Ceased
- 2013-06-28 SG SG10201703489VA patent/SG10201703489VA/en unknown
- 2013-06-28 MX MX2015000190A patent/MX336715B/es unknown
- 2013-06-28 UA UAA201413826A patent/UA121959C2/uk unknown
- 2013-06-28 SM SM20180612T patent/SMT201800612T1/it unknown
- 2013-06-28 TW TW105120026A patent/TWI587869B/zh active
- 2013-06-28 CN CN201710840314.6A patent/CN107596357A/zh active Pending
- 2013-06-28 MY MYPI2019006401A patent/MY192068A/en unknown
- 2013-06-28 CA CA2877517A patent/CA2877517C/en active Active
- 2013-06-28 CA CA3008945A patent/CA3008945A1/en not_active Abandoned
- 2013-06-28 TR TR2018/15811T patent/TR201815811T4/tr unknown
- 2013-06-28 UA UAA201908350A patent/UA129561C2/uk unknown
- 2013-06-28 ES ES13809853.8T patent/ES2689468T3/es active Active
- 2013-06-28 BR BR112014032567-7A patent/BR112014032567B1/pt active IP Right Grant
- 2013-06-28 NZ NZ733366A patent/NZ733366A/en unknown
- 2013-06-28 SG SG11201408761VA patent/SG11201408761VA/en unknown
- 2013-06-28 EA EA201492177A patent/EA034549B1/ru active IP Right Maintenance
- 2013-06-28 EP EP18193801.0A patent/EP3441398A1/en active Pending
- 2013-06-28 HU HUE13809853A patent/HUE040769T2/hu unknown
- 2013-06-28 HR HRP20181897TT patent/HRP20181897T1/hr unknown
- 2013-06-28 TW TW102123353A patent/TWI553120B/zh active
- 2013-06-28 SI SI201331176T patent/SI2867245T1/sl unknown
- 2013-06-28 PL PL13809853T patent/PL2867245T3/pl unknown
- 2013-06-28 MY MYPI2014003472A patent/MY157087A/en unknown
- 2013-06-28 PT PT13809853T patent/PT2867245T/pt unknown
- 2013-06-28 NZ NZ703093A patent/NZ703093A/en unknown
- 2013-06-28 DK DK13809853.8T patent/DK2867245T3/en active
- 2013-06-28 CN CN201380042665.2A patent/CN104583225A/zh active Pending
- 2013-06-28 MX MX2016001228A patent/MX366906B/es unknown
- 2013-06-28 RS RS20181324A patent/RS58005B1/sr unknown
- 2013-06-28 HK HK15110042.0A patent/HK1209431A1/xx unknown
- 2013-06-28 JP JP2015520567A patent/JP6171007B2/ja active Active
- 2013-06-28 AU AU2013282395A patent/AU2013282395C1/en active Active
- 2013-06-28 EP EP13809853.8A patent/EP2867245B1/en not_active Revoked
- 2013-06-28 NZ NZ743910A patent/NZ743910A/en unknown
- 2013-06-28 LT LTEP13809853.8T patent/LT2867245T/lt unknown
- 2013-07-01 AR ARP130102350 patent/AR091647A1/es not_active Application Discontinuation
- 2013-09-26 KR KR1020130114704A patent/KR20140004603A/ko not_active Ceased
-
2014
- 2014-12-17 CR CR20140588A patent/CR20140588A/es unknown
- 2014-12-17 IL IL236315A patent/IL236315A/en active IP Right Grant
- 2014-12-19 ZA ZA201409397A patent/ZA201409397B/en unknown
- 2014-12-19 DO DO2014000294A patent/DOP2014000294A/es unknown
- 2014-12-22 PH PH12014502871A patent/PH12014502871A1/en unknown
- 2014-12-26 CO CO14284199A patent/CO7240396A2/es unknown
- 2014-12-29 GT GT201400303A patent/GT201400303A/es unknown
- 2014-12-29 CL CL2014003567A patent/CL2014003567A1/es unknown
-
2015
- 2015-03-30 US US14/673,607 patent/US9492511B2/en active Active
- 2015-10-16 PH PH12015502408A patent/PH12015502408B1/en unknown
-
2016
- 2016-01-27 AU AU2016200469A patent/AU2016200469B2/en active Active
- 2016-03-24 JP JP2016060910A patent/JP6505629B2/ja active Active
- 2016-09-28 US US15/279,018 patent/US10344270B2/en active Active
- 2016-11-03 IL IL248727A patent/IL248727A0/en active IP Right Grant
-
2018
- 2018-01-11 AU AU2018200230A patent/AU2018200230B2/en active Active
- 2018-03-30 JP JP2018067404A patent/JP2018121645A/ja not_active Withdrawn
- 2018-05-17 ZA ZA2018/03289A patent/ZA201803289B/en unknown
- 2018-07-05 HK HK18108732.6A patent/HK1249026A1/zh unknown
- 2018-07-05 HK HK18108734.4A patent/HK1249027A1/zh unknown
- 2018-08-21 IL IL261264A patent/IL261264B/en unknown
- 2018-11-28 CY CY20181101263T patent/CY1121519T1/el unknown
-
2019
- 2019-05-20 US US16/417,440 patent/US20190359958A1/en not_active Abandoned
- 2019-05-28 KR KR1020190062745A patent/KR20190064542A/ko not_active Ceased
-
2020
- 2020-01-02 PH PH12020500027A patent/PH12020500027A1/en unknown
- 2020-03-05 JP JP2020037811A patent/JP7594365B2/ja active Active
- 2020-11-06 US US17/092,034 patent/US11530393B2/en active Active
- 2020-12-16 KR KR1020200176714A patent/KR20200143339A/ko not_active Ceased
-
2021
- 2021-10-06 IL IL287057A patent/IL287057A/en unknown
- 2021-12-28 KR KR1020210189927A patent/KR20220002227A/ko not_active Ceased
-
2022
- 2022-11-03 US US18/052,442 patent/US20240043817A1/en not_active Abandoned
-
2024
- 2024-04-24 US US18/645,049 patent/US12359178B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015523072A5 (enExample) | ||
| AR091647A1 (es) | Purificacion de iduronato-2-sulfatasa | |
| TR201900128T4 (tr) | Amino asit 1'de ve 3'te modifiye edilmiş siklosporin analoğu moleküller. | |
| HRP20160490T4 (hr) | Pripravak i oblik koji sadrže rekombinantnu humanu iduronat-2-sulfatazu te postupci njihove pripreme | |
| HRP20220455T1 (hr) | Modificirane aminokiseline koje sadrže azid grupu | |
| BR112012033703A2 (pt) | polipeptídeo tendo atividade beta-glicosidase e seus usos | |
| JP2007175057A5 (enExample) | ||
| BR112014007469A2 (pt) | arcabouços de proteína com base em repetição de fibronectina tipo iii com superfícies de ligação alternativas | |
| HRP20190982T1 (hr) | Peptidi i njihova uporaba | |
| BR112013031262A2 (pt) | "exotoxinas a de pseudomonas com menos epítopos imunogênicos de célula b e t, e seu uso no tratamento e prevenção de câncer, bem como molécula quimérica, ácido nucleico, vetor de expressão, células, composição farmacêutica e métodos para inibir crescimento de célula-alvo e de produção de endotoxinas a de pseudomonas e de molécula quimérica". | |
| WO2010057203A3 (en) | Hdl particles for delivery of nucleic acids | |
| BR112012033714A2 (pt) | polipeptídeo com atividade de acetil xilano esterase e seus usos. | |
| WO2011097381A3 (en) | Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof | |
| BR112015009201A2 (pt) | composição compreendeendo um polipeptídeo recombinante, ácido nucleico codificando o mesmo, célula hospedeira, bem como métodos para produzir uma beta-glucosidase e para hidrolisar um substrato de biomassa lignocelulósica | |
| JP2013503110A5 (enExample) | ||
| JP2015533791A5 (enExample) | ||
| HK1206763A1 (en) | Charged nutritive fragments, proteins and methods | |
| JP2014510101A5 (enExample) | ||
| JP2010265269A5 (enExample) | ||
| HRP20161009T1 (hr) | Modificirani omci kao inhibitor komplementa | |
| EP3263123A3 (en) | Shk-based pharmaceutical compositions and methods of manufacturing and using the same | |
| BR112012033396A2 (pt) | Polipetídeo tendo atividade swollenin e seus usos. | |
| BR112012008655A2 (pt) | formulação detergente em dose distinta ou única. | |
| WO2011156252A3 (en) | Sulfation of wnt pathway proteins | |
| WO2009108713A3 (en) | Topical compositions and methods utilizing peptides containing lipid-modified cysteine-containing peptides |